AMOXICILLIN (AMOXYCILLIN) with CLAVULANIC ACID

This document should be read in conjunction with this DISCLAIMER

Antimicrobial Restriction – Unrestricted

| Presentation | Tablet: 875mg/125mg  
Oral liquid: 400mg/57mg in 5mL  
Vial: 1000/200mg (1.2g) |
|--------------|-----------------------------------------|
| Dose         | **Cystitis:**  
Oral:  
875/125mg 12 hourly for 5 to 7 days  
**Pelvic Inflammatory Disease:**  
Oral:  
875/125mg 12 hourly for 2 to 4 weeks (once on oral therapy)  
**Endometritis**  
*For less unwell patients where oral antibiotics are deemed sufficient or for empiric step down therapy*  
Oral:  
875/125mg 12 hourly for 2 weeks  
**Prophylaxis for operative vaginal delivery**  
*To minimise neonatal exposure, only administer AFTER cord clamping*  
IV:  
1.2g (as a single dose) within 6 hours of delivery  
Oral (only if IV access not achieved):  
875/125mg (as a single dose) within 6 hours of delivery |
| Administration | **Oral:**  
To be taken immediately before food, to maximise absorption |
### Amoxicillin with clavulanic acid – Adult

**IV injection:**

**Step 1 reconstitution:** Reconstitute the 1.2g vial with 20mL of water for injections. Concentration is amoxicillin 50mg/mL.

**Step 2 administration:** Inject SLOWLY over 3 to 4 minutes

<table>
<thead>
<tr>
<th>Pregnancy</th>
<th>1&lt;sup&gt;st&lt;/sup&gt; Trimester: Safe to use</th>
<th>2&lt;sup&gt;nd&lt;/sup&gt; Trimester: Safe to use</th>
<th>3&lt;sup&gt;rd&lt;/sup&gt; Trimester: Safe to use</th>
<th><strong>NOTE:</strong> Should be avoided in women with preterm rupture of membranes due to a possible increased risk of neonatal necrotising enterocolitis (NEC).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breastfeeding</td>
<td>Safe to use</td>
<td>Safe to use</td>
<td>Safe to use</td>
<td>Safe to use</td>
</tr>
</tbody>
</table>

**Monitoring**

Monitor complete blood count and renal and hepatic function during prolonged high-dose treatment (>10 days)

**Clinical guidelines and policies**


**References**


### Keywords:
- Amoxicillin, amoxicillin, clavulanic acid, clavulanate, augmentin, aug DF, UTI, urinary tract infection, cystitis, PID, pelvic inflammatory disease, STI, endometritis, salpingitis, parametritis, oophritis, pelvic peritonitis, instrumental birth, instrumental vaginal delivery, surgical prophylaxis

### Publishing:
- ☑ Intranet  ☑ Internet

### Document owner:
- Chief Pharmacist

### Author / Reviewer:
- Pharmacy Department

### Date first issued:
- November 2014

### Version:
- 3.2

### Last reviewed:
- March 2017, Jan 2019, amended Jul 2020 (IV information added as per O&G Guideline update)

### Next review date:
- Jan 2022

### Endorsed by:
- Medicine and Therapeutic Committee

### Date:
- Jan 2019

### Standards Applicable:
- NSQHS Standards: 1 Governance, 3 Infection Control, 4 Medication Safety

**Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.**

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2020